Here are the 10-K annual reports from Apyx Medical Corporation (APYX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow APYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APYX filings page.
Apyx Medical Corporation reports its annual results highlighting ongoing operating losses alongside new product launches and financing actions. For the year ended December 31, 2025, it recorded a loss from operations of $6.4 million and used $8.0 million of cash in operations, while holding $31.7 million in cash and cash equivalents.
The company advanced its surgical aesthetics portfolio, receiving 510(k) clearance for its AYON body contouring system and beginning a commercial launch in September 2025, and it launched Renuvion in China after local clearance. It also completed a $7.0 million registered direct offering in 2024, a follow-on equity offering in 2025 with net proceeds of about $9.1 million, and put in place a shelf registration for up to $100 million of securities.
Apyx cut costs via a 2024 restructuring that reduced its U.S. workforce by nearly 25%, helping bring 2025 operating expenses below $40.0 million versus $48.2 million in 2024. As of December 31, 2025, it remained in compliance with covenants under its Perceptive Credit Agreement, which includes minimum revenue and maximum operating expense targets and a required $3.0 million cash balance.